MILLIPLEX^® Human Complement Panel

The complement system consists of many plasma proteins that assist, or complement, the ability of phagocytic cells and antibodies to clear pathogens. Although it is part of the innate immune system, it can be recruited and activated by the adaptive immune system. The complement proteins and glycoproteins that are synthesized primarily by hepatocytes normally circulate as inactive pro-proteins. Once stimulated the result of the cascade is a massive amplification of response and activation of the membrane attack complex (C5b-9), which forms a transmembrane pore causing osmotic lysis of target cells. The complement pathway may also form soluble C5b-9, as well as intermediate isoforms, stabilized by regulatory proteins. These soluble complexes are unable to insert into the lipid membrane, and their role in complement pathways is an area of ongoing research.

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Analyze C5b-9 in human serum, plasma, and cell culture supernatants.

Analytes included: C5b-9

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.